

## **Transfer of 16 Long-Listed Products in Japan to LTL Pharma: Closing of Asset Purchase Agreement**

Tokyo, April 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) confirmed the relevant closing conditions are met on April 28, 2017 to allow the transfer of the assets related to Astellas’ 16 long-listed products (the “Products”) in Japan to LTL Pharma.

On March 28, 2017, Astellas and LTL Pharma entered into an Asset Purchase Agreement, under which Astellas will transfer to LTL Pharma its marketing authorization of the Products in Japan, supply business of active pharmaceutical ingredients/bulk of the Products to third parties in and outside of Japan and royalty business of the Products.

*note:* The Products sold by Astellas subsidiaries outside of Japan will be supplied by LTL Pharma to Astellas subsidiaries after the closing, and Astellas subsidiaries will maintain commercial responsibility.

Astellas and LTL Pharma have now satisfied the pre-agreed conditions to close the transaction, with Astellas having received 20.1 billion yen as a result. Astellas and LTL Pharma will continue to work closely together with the aim of securing an effective transition with continued supply to patients.

Astellas reflected the impact from this closing of transaction in its financial forecasts of the current fiscal year ending March 31, 2018, disclosed on April 27, 2017.

#####

### **About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare

business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

### **Cautionary Notes**

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

### **Contacts for inquiries or additional information:**

---

Astellas Pharma Inc.  
Corporate Communications  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473